Base de dados : MEDLINE
Pesquisa : D12.776.543.750.720 [Categoria DeCS]
Referências encontradas : 9655 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 966 ir para página                         

  1 / 9655 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29329072
[Au] Autor:De Prins A; Martin C; Van Wanseele Y; Skov LJ; Tömböly C; Tourwé D; Caveliers V; Van Eeckhaut A; Holst B; Rosenkilde MM; Smolders I; Ballet S
[Ad] Endereço:Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Brussels, Belgium; Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Center for Neurosciences (C4N), Vrije Universiteit Brussel, Laarbee
[Ti] Título:Development of potent and proteolytically stable human neuromedin U receptor agonists.
[So] Source:Eur J Med Chem;144:887-897, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Neuromedin U (NMU) is a highly conserved endogenous peptide that is involved in a wide range of physiological processes such as regulation of feeding behavior, the stress response and nociception. The major limitation to use NMU as a therapeutic is its short half-life. Here, we describe the development of a set of novel NMU-analogs based on NMU-8, by introducing unnatural amino acids into the native sequence. This approach shows that it is possible to generate molecules with increased potency and improved plasma stability without major changes of the peptidic nature or the introduction of large conjugates. When compared to the native NMU-8 peptide, compounds 16, 18 and 20 have potent agonist activity and affinity for both NMU receptors. Selectivity towards NMUR1 was observed when the Phe residue in position 4 was modified, whereas higher potencies at NMUR2 were found when substitutions of the Pro residue in position 6 were executed. To study the effect of the modifications on the proteolytic stability of the molecules, an in vitro stability assay in human plasma at 37 °C was performed. All analyzed analogs possessed an increased resistance against enzymatic degradation in human plasma resulting in half-lifes from 4 min for NMU-8, up to more than 23 h for compound 42.
[Mh] Termos MeSH primário: Neuropeptídeos/farmacologia
Proteólise/efeitos dos fármacos
Receptores de Neurotransmissores/agonistas
[Mh] Termos MeSH secundário: Relação Dose-Resposta a Droga
Seres Humanos
Estrutura Molecular
Neuropeptídeos/síntese química
Neuropeptídeos/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neuropeptides); 0 (Receptors, Neurotransmitter); 0 (neuromedin U receptor); 98530-27-9 (neuromedin U 8)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE


  2 / 9655 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29216460
[Au] Autor:Maher MP; Matta JA; Gu S; Seierstad M; Bredt DS
[Ad] Endereço:Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA 92121, USA.
[Ti] Título:Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins.
[So] Source:Neuron;96(5):989-1001, 2017 Dec 06.
[Is] ISSN:1097-4199
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Targeted therapy for neuropsychiatric disorders requires selective modulation of dysfunctional neuronal pathways. Receptors relevant to CNS disorders typically have associated proteins discretely expressed in specific neuronal pathways; these accessory proteins provide a new dimension for drug discovery. Recent studies show that targeting a TARP auxiliary subunit of AMPA receptors selectively modulates neuronal excitability in specific forebrain pathways relevant to epilepsy. Other medicinally important ion channels, gated by glutamate, γ-aminobutyric acid (GABA), and acetylcholine, also have associated proteins, which may be druggable. This emerging pharmacology of receptor-associated proteins provides a new approach for improving drug efficacy while mitigating side effects.
[Mh] Termos MeSH primário: Neurofarmacologia
Receptores de Neurotransmissores/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Proteínas do Tecido Nervoso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Nerve Tissue Proteins); 0 (Receptors, Neurotransmitter)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE


  3 / 9655 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28935264
[Au] Autor:Nishizawa N; Kanematsu-Yamaki Y; Funata M; Nagai H; Shimizu A; Fujita H; Sakamoto J; Takekawa S; Asami T
[Ad] Endereço:Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Fujisawa 251-8555, Japan. Electronic address: naoki.nishizawa@takeda.com.
[Ti] Título:A potent neuromedin U receptor 2-selective alkylated peptide.
[So] Source:Bioorg Med Chem Lett;27(20):4626-4629, 2017 10 15.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Neuromedin U (NMU) mediates various physiological functions via NMUR1 and NMUR2 receptors. NMUR2 has been considered a promising treatment option for diabetes and obesity. Although NMU-8, a shorter peptide, has potent agonist activity for both receptors, it is metabolically unstable. Therefore, NMU-8 analogs modified with long-chain alkyl moieties via a linker were synthesized. An octadecanoyl analog (17) with amino acid substitutions [αMePhe , Nle , and Arg(Me) ] and a linker [Tra-γGlu-PEG(2)] dramatically increased NMUR2 selectivity, with retention of high agonist activity. Subcutaneous administration of 17 induced anorectic activity in C57BL/6J mice. Owing to its high metabolic stability, 17 would be useful in clarifying the physiological role and therapeutic application of NMU.
[Mh] Termos MeSH primário: Depressores do Apetite/metabolismo
Peptídeos/metabolismo
Receptores de Neurotransmissores/metabolismo
[Mh] Termos MeSH secundário: Alquilação
Sequência de Aminoácidos
Animais
Depressores do Apetite/química
Depressores do Apetite/farmacologia
Ingestão de Alimentos/efeitos dos fármacos
Seres Humanos
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Peptídeos/agonistas
Receptores de Neurotransmissores/antagonistas & inibidores
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Appetite Depressants); 0 (Peptides); 0 (Receptors, Neurotransmitter); 0 (neuromedin U receptor)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171125
[Lr] Data última revisão:
171125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170923
[St] Status:MEDLINE


  4 / 9655 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28864416
[Au] Autor:Zhang W; Sakoda H; Miura A; Shimizu K; Mori K; Miyazato M; Takayama K; Hayashi Y; Nakazato M
[Ad] Endereço:Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
[Ti] Título:Neuromedin U suppresses glucose-stimulated insulin secretion in pancreatic ß cells.
[So] Source:Biochem Biophys Res Commun;493(1):677-683, 2017 Nov 04.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neuromedin U (NMU), a highly conserved peptide in mammals, is implicated in energy homeostasis and glycemic control, and may also be involved in the regulation of adipoinsular axis function. However, the role of NMU in regulating insulin secretion has not been clearly established. In this study, we investigated the role of NMU in the regulation of insulin secretion both in vitro and in vivo. We found that NMU and NMU receptor (NMUR) 1 were expressed in mouse islets and ß cell-derived MIN6-K8 cells. In mice, NMU suppressed glucose-stimulated insulin secretion (GSIS) both in vitro and in vivo. Additionally, an NMUR1 agonist inhibited GSIS in both MIN6-K8 cells and mice islets. Moreover, NMU attenuated intracellular Ca influx in MIN6-K8 cells, potentially causing a decrease in insulin secretion. siNmu-transfected MIN6-K8 cells showed elevated GSIS. Treatment with anti-NMU IgG increased GSIS in isolated mouse pancreatic islets. These results suggested that NMU can act directly on ß cells through NMUR1 in an autocrine or paracrine fashion to suppress insulin secretion. Collectively, our results highlight the crucial role of NMU in suppressing pancreatic insulin secretion, and may improve our understanding of glucose homeostasis.
[Mh] Termos MeSH primário: Sinalização do Cálcio/fisiologia
Glucose/metabolismo
Células Secretoras de Insulina/metabolismo
Insulina/secreção
Neuropeptídeos/metabolismo
Receptores de Neurotransmissores/metabolismo
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Células Cultivadas
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); 0 (Neuropeptides); 0 (Receptors, Neurotransmitter); 0 (neuromedin U receptor); 117505-80-3 (neuromedin U); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170903
[St] Status:MEDLINE


  5 / 9655 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28858617
[Au] Autor:Watanabe K; Chiu H; Pfeiffer BD; Wong AM; Hoopfer ED; Rubin GM; Anderson DJ
[Ad] Endereço:Division of Biology and Biological Engineering 156-29 and the Tianqiao and Chrissy Chen Institute for Neuroscience, California Institute of Technology, Pasadena, CA, USA; Howard Hughes Medical Institute.
[Ti] Título:A Circuit Node that Integrates Convergent Input from Neuromodulatory and Social Behavior-Promoting Neurons to Control Aggression in Drosophila.
[So] Source:Neuron;95(5):1112-1128.e7, 2017 Aug 30.
[Is] ISSN:1097-4199
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Diffuse neuromodulatory systems such as norepinephrine (NE) control brain-wide states such as arousal, but whether they control complex social behaviors more specifically is not clear. Octopamine (OA), the insect homolog of NE, is known to promote both arousal and aggression. We have performed a systematic, unbiased screen to identify OA receptor-expressing neurons (OARNs) that control aggression in Drosophila. Our results uncover a tiny population of male-specific aSP2 neurons that mediate a specific influence of OA on aggression, independent of any effect on arousal. Unexpectedly, these neurons receive convergent input from OA neurons and P1 neurons, a population of FruM neurons that promotes male courtship behavior. Behavioral epistasis experiments suggest that aSP2 neurons may constitute an integration node at which OAergic neuromodulation can bias the output of P1 neurons to favor aggression over inter-male courtship. These results have potential implications for thinking about the role of related neuromodulatory systems in mammals.
[Mh] Termos MeSH primário: Agressão/fisiologia
Proteínas de Drosophila/fisiologia
Drosophila/citologia
Drosophila/fisiologia
Vias Neurais
Neurônios/fisiologia
Receptores de Neurotransmissores/fisiologia
Comportamento Social
[Mh] Termos MeSH secundário: Animais
Animais Geneticamente Modificados
Nível de Alerta/fisiologia
Corte
Proteínas de Drosophila/genética
Interneurônios/fisiologia
Masculino
Receptores de Neurotransmissores/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drosophila Proteins); 0 (OAMB protein, Drosophila); 0 (Receptors, Neurotransmitter)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE


  6 / 9655 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28657315
[Au] Autor:Kanematsu-Yamaki Y; Nishizawa N; Kaisho T; Nagai H; Mochida T; Asakawa T; Inooka H; Dote K; Fujita H; Matsumiya K; Hirabayashi H; Sakamoto J; Ohtaki T; Takekawa S; Asami T
[Ad] Endereço:Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
[Ti] Título:Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
[So] Source:J Med Chem;60(14):6089-6097, 2017 Jul 27.
[Is] ISSN:1520-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neuromedin U (NMU) is a neuropeptide that mediates a variety of physiological functions via its receptors, NMUR1 and NMUR2. Recently, there has been an increased focus on NMU as a promising treatment option for diabetes and obesity. A short form of NMU (NMU-8) has potent agonist activity for both receptors but is metabolically unstable. Therefore, we designed and synthesized NMU-8 analogues modified by polyethylene glycol (PEG; molecular weight, 20 kDa; PEG20k) via a linker. 3-(2-Naphthyl)alanine substitution at position 19 increased NMUR2 selectivity of NMU-8 analogues with retention of high agonist activity. Compound 37, an NMUR2-selective PEG20k analogue containing piperazin-1-ylacetyl linker, exhibited a potent body weight-lowering effect with concomitant inhibition of food intake in a dose-dependent manner (body weight loss of 12.4% at 30 nmol/kg) by once-daily repeated dosing for 2 weeks in mice with diet-induced obesity.
[Mh] Termos MeSH primário: Fármacos Antiobesidade/síntese química
Neuropeptídeos/química
Obesidade/tratamento farmacológico
Fragmentos de Peptídeos/síntese química
Polietilenoglicóis/química
Receptores de Neurotransmissores/agonistas
[Mh] Termos MeSH secundário: Animais
Fármacos Antiobesidade/farmacocinética
Fármacos Antiobesidade/farmacologia
Peso Corporal/efeitos dos fármacos
Gorduras na Dieta/administração & dosagem
Masculino
Camundongos Endogâmicos C57BL
Naftalenos/síntese química
Naftalenos/farmacocinética
Naftalenos/farmacologia
Obesidade/fisiopatologia
Fragmentos de Peptídeos/farmacocinética
Fragmentos de Peptídeos/farmacologia
Piperazinas/síntese química
Piperazinas/farmacocinética
Piperazinas/farmacologia
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 0 (Dietary Fats); 0 (Naphthalenes); 0 (Neuropeptides); 0 (Peptide Fragments); 0 (Piperazines); 0 (Receptors, Neurotransmitter); 0 (neuromedin U receptor); 117505-80-3 (neuromedin U); 30IQX730WE (Polyethylene Glycols)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jmedchem.7b00330


  7 / 9655 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28548497
[Au] Autor:Takayama K; Mori K; Tanaka A; Nomura E; Sohma Y; Mori M; Taguchi A; Taniguchi A; Sakane T; Yamamoto A; Minamino N; Miyazato M; Kangawa K; Hayashi Y
[Ad] Endereço:Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences , 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
[Ti] Título:Discovery of a Human Neuromedin U Receptor 1-Selective Hexapeptide Agonist with Enhanced Serum Stability.
[So] Source:J Med Chem;60(12):5228-5234, 2017 Jun 22.
[Is] ISSN:1520-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neuromedin U (NMU) activates two NMU receptors (NMUR1 and NMUR2) and is a useful antiobesity drug lead. We report discovery of a hexapeptide agonist, 2-thienylacetyl-Trp -Phe(4-F) -Arg -Pro -Arg -Asn -NH (4). However, the NMUR1 selectivity and serum stability of this agonist were unsatisfactory. Through a structure-activity relationship study focused on residue 2 of agonist 4, serum stability, and pharmacokinetic properties, we report here the discovery of a novel NMUR1 selective hexapeptide agonist 7b that suppresses body weight gain in mice.
[Mh] Termos MeSH primário: Peptídeos/farmacologia
Receptores de Neurotransmissores/agonistas
Ganho de Peso/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Cálcio/metabolismo
Avaliação Pré-Clínica de Medicamentos/métodos
Estabilidade de Medicamentos
Seres Humanos
Masculino
Peptídeos/sangue
Peptídeos/farmacocinética
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (NMUR1 protein, human); 0 (Peptides); 0 (Receptors, Neurotransmitter); 0 (neuromedin U receptor); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170811
[Lr] Data última revisão:
170811
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170527
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jmedchem.7b00694


  8 / 9655 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28476646
[Au] Autor:Rao A; Herr DR
[Ad] Endereço:Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore.
[Ti] Título:G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells.
[So] Source:Biochim Biophys Acta;1864(7):1318-1327, 2017 07.
[Is] ISSN:0006-3002
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Dysregulation of G protein-coupled receptors (GPCRs) is known to be involved in the pathogenesis of a variety of diseases, including cancer initiation and progression. Within this family, approximately 140 GPCRs have no known endogenous ligands and these "orphan" GPCRs remain poorly characterized. The orphan GPCR GPR19 was identified and cloned 2 decades ago, but relatively little is known about its physio-pathological relevance. We observed its expression to be elevated in breast cancers and therefore sought to investigate its potential role in breast cancer pathology. In this work, we show that overexpression of GPR19 drives mesenchymal-like breast cancer cells to adopt an epithelial-like phenotype, as demonstrated by the upregulation in E-cadherin expression and changes in functional behavior. We confirm a previous report that a peptide, adropin, is an endogenous ligand for GPR19. We further show that adropin-mediated activation of GPR19 activates the MAPK/ERK1/2 pathway, which is essential for the observed upregulation in E-cadherin and accompanying phenotypic changes. The recapitulation of epithelial characteristics at the secondary tumor sites is now understood to be an essential step in the colonization process. Taken together our work shows for the first time that GPR19 plays a potential role in metastasis by promoting the mesenchymal-epithelial transition (MET) through the ERK/MAPK pathway, thus facilitating colonization of metastatic breast tumor cells.
[Mh] Termos MeSH primário: Caderinas/metabolismo
Movimento Celular
Regulação Neoplásica da Expressão Gênica
Proteínas do Tecido Nervoso/metabolismo
Receptores Acoplados a Proteínas-G/metabolismo
Receptores de Neurotransmissores/metabolismo
[Mh] Termos MeSH secundário: Proteínas Sanguíneas/metabolismo
Caderinas/genética
Adesão Celular
Transição Epitelial-Mesenquimal
Células HEK293
Seres Humanos
Sistema de Sinalização das MAP Quinases
Células MCF-7
Proteínas do Tecido Nervoso/genética
Peptídeos/metabolismo
Receptores Acoplados a Proteínas-G/genética
Receptores de Neurotransmissores/genética
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Blood Proteins); 0 (Cadherins); 0 (Enho protein, human); 0 (GPR19 protein, human); 0 (Nerve Tissue Proteins); 0 (Peptides); 0 (Receptors, G-Protein-Coupled); 0 (Receptors, Neurotransmitter)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170507
[St] Status:MEDLINE


  9 / 9655 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28412965
[Au] Autor:Chiu WZ; Donker Kaat L; Boon AJW; Kamphorst W; Schleicher A; Zilles K; van Swieten JC; Palomero-Gallagher N
[Ad] Endereço:Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.
[Ti] Título:Multireceptor fingerprints in progressive supranuclear palsy.
[So] Source:Alzheimers Res Ther;9(1):28, 2017 Apr 17.
[Is] ISSN:1758-9193
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Progressive supranuclear palsy (PSP) with a frontal presentation, characterized by cognitive deficits and behavioral changes, has been recognized as an early clinical picture, distinct from the classical so-called Richardson and parkinsonism presentations. The midcingulate cortex is associated with executive and attention tasks and has consistently been found to be impaired in imaging studies of patients with PSP. The aim of the present study was to determine alterations in neurotransmission underlying the pathophysiology of PSP, as well as their significance for clinically identifiable PSP subgroups. METHODS: In vitro receptor autoradiography was used to quantify densities of 20 different receptors in the caudate nucleus and midcingulate area 24' of patients with PSP (n = 16) and age- and sex-matched control subjects (n = 14). RESULTS: Densities of γ-aminobutyric acid type B, peripheral benzodiazepine, serotonin receptor type 2, and N-methyl-D-aspartate receptors were significantly higher in area 24' of patients with PSP, where tau impairment was stronger than in the caudate nucleus. Kainate and nicotinic cholinergic receptor densities were significantly lower, and adenosine receptor type 1 (A ) receptors significantly higher, in the caudate nucleus of patients with PSP. Receptor fingerprints also segregated PSP subgroups when clinical parameters such as occurrence of frontal presentation and tau pathology severity were taken into consideration. CONCLUSIONS: We demonstrate, for the first time to our knowledge, that kainate and A receptors are altered in PSP and that clinically identifiable PSP subgroups differ at the neurochemical level. Numerous receptors were altered in the midcingulate cortex, further suggesting that it may prove to be a key region in PSP. Finally, we add to the evidence that nondopaminergic systems play a role in the pathophysiology of PSP, thus highlighting potential novel treatment strategies.
[Mh] Termos MeSH primário: Núcleo Caudado/metabolismo
Giro do Cíngulo/metabolismo
Receptores de Neurotransmissores/metabolismo
Paralisia Supranuclear Progressiva/metabolismo
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Autorradiografia
Núcleo Caudado/patologia
Estudos de Coortes
Feminino
Giro do Cíngulo/patologia
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Paralisia Supranuclear Progressiva/patologia
Transmissão Sináptica/fisiologia
Proteínas tau/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MAPT protein, human); 0 (Receptors, Neurotransmitter); 0 (tau Proteins)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170418
[St] Status:MEDLINE
[do] DOI:10.1186/s13195-017-0259-5


  10 / 9655 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28320311
[Au] Autor:Janusonis S
[Ad] Endereço:Department of Psychological and Brain Sciences, University of California, Santa Barbara, CA, 93106-9660, USA. skirmantas.janusonis@psych.ucsb.edu.
[Ti] Título:A receptor-based analysis of local ecosystems in the human brain.
[So] Source:BMC Neurosci;18(1):33, 2017 Mar 20.
[Is] ISSN:1471-2202
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: As a complex system, the brain is a self-organizing entity that depends on local interactions among cells. Its regions (anatomically defined nuclei and areas) can be conceptualized as cellular ecosystems, but the similarity of their functional profiles is poorly understood. The study used the Allen Human Brain Atlas to classify 169 brain regions into hierarchically-organized environments based on their expression of 100 G protein-coupled neurotransmitter receptors, with no a priori reference to the regions' positions in the brain's anatomy or function. The analysis was based on hierarchical clustering, and multiscale bootstrap resampling was used to estimate the reliability of detected clusters. RESULTS: The study presents the first unbiased, hierarchical tree of functional environments in the human brain. The similarity of brain regions was strongly influenced by their anatomical proximity, even when they belonged to different functional systems. Generally, spatial vicinity trumped long-range projections or network connectivity. The main cluster of brain regions excluded the dentate gyrus of the hippocampus. The nuclei of the amygdala formed a cluster irrespective of their striatal or pallial origin. In its receptor profile, the hypothalamus was more closely associated with the midbrain than with the thalamus. The cerebellar cortical areas formed a tight and exclusive cluster. Most of the neocortical areas (with the exception of some occipital areas) clustered in a large, statistically well supported group that included no other brain regions. CONCLUSIONS: This study adds a new dimension to the established classifications of brain divisions. In a single framework, they are reconsidered at multiple scales-from individual nuclei and areas to their groups to the entire brain. The analysis provides support for predictive models of brain self-organization and adaptation.
[Mh] Termos MeSH primário: Encéfalo/metabolismo
Receptores Acoplados a Proteínas-G/metabolismo
Receptores de Neurotransmissores/metabolismo
[Mh] Termos MeSH secundário: Adulto
Atlas como Assunto
Encéfalo/anatomia & histologia
Análise por Conglomerados
Feminino
Seres Humanos
Masculino
Meia-Idade
RNA Mensageiro/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RNA, Messenger); 0 (Receptors, G-Protein-Coupled); 0 (Receptors, Neurotransmitter)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170322
[St] Status:MEDLINE
[do] DOI:10.1186/s12868-017-0355-2



página 1 de 966 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde